Thérapies de Conversion

Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.

Lin KY, Zhang JX, Lin ZW, Chen QJ, Luo LP, Chen JH, Wang K, Tai S, Zhang ZB, Wang SF, Li JD, Wang K, Zheng L, Zheng SM, Wu MM, Lin KC, Yang T, Zeng YY

Front Immunol . 2024;15 :1308543

📅 01/01/2024 PMID : 38433845 DOI : 10.3389/fimmu.2024.1308543

Résumé

BACKGROUND: This study evaluates the efficacy of alpha-fetoprotein (AFP) response as a surrogate marker for determining recurrence-free survival (RFS) in patients with unresectable hepatocellular carcinoma (uHCC) who undergo salvage hepatectomy following conversion therapy with tyrosine kinase inhibitor (TKI) and anti-PD-1 antibody-based regimen.METHODS: This multicenter retrospective study included 74 patients with uHCC and positive AFP (>20 ng/mL) at diagnosis, who underwent salvage hepatectomy after treatment with TKIs and anti-PD-1 antibody-based regimens. The association between AFP response-defined as a ≥ 80% decrease in final AFP levels before salvage hepatectomy from diagnosis-and RFS post-hepatectomy was investigated.RESULTS: AFP responders demonstrated significantly better postoperative RFS compared to non-responders (